Home

DexCom, Inc. - Common Stock (DXCM)

87.62
0.00 (0.00%)

Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes

Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users.

SummaryNewsPress ReleasesChartHistoricalFAQ
2 Healthcare Stocks to Buy Hand Over Fist in Januaryfool.com
Via The Motley Fool · January 16, 2025
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?chartmill.com
Exploring the Growth Potential of DEXCOM INC (NASDAQDXCM) as It Nears a Breakout.
Via Chartmill · January 16, 2025
Expert Outlook: DexCom Through The Eyes Of 11 Analystsbenzinga.com
Via Benzinga · January 16, 2025
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursdaybenzinga.com
Via Benzinga · January 16, 2025
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursdaybenzinga.com
Via Benzinga · January 16, 2025
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market.investors.com
Smart rings are one of the hottest consumer electronics categories, as evidenced by exhibitors at CES 2025. Oura leads the market.
Via Investor's Business Daily · January 9, 2025
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.chartmill.com
DEXCOM INC (NASDAQDXCM) qualifies as a high growth stock and is consolidating.
Via Chartmill · December 25, 2024
1 Reason to Sell DexCom Stock, and 1 Reason to Buyfool.com
Via The Motley Fool · December 21, 2024
Peering Into DexCom's Recent Short Interestbenzinga.com
Via Benzinga · December 16, 2024
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025fool.com
Via The Motley Fool · January 8, 2025
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024fool.com
Via The Motley Fool · January 4, 2025
Key Takeaways From DexCom Analyst Ratingsbenzinga.com
Via Benzinga · December 9, 2024
3 Reasons to Buy DexCom Stock Like There's No Tomorrowfool.com
Via The Motley Fool · December 2, 2024
Exploring the Growth Potential of NASDAQ:DXCM as It Nears a Breakout.chartmill.com
Exploring the Growth Potential of DEXCOM INC (NASDAQDXCM) as It Nears a Breakout.
Via Chartmill · December 2, 2024
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukosbenzinga.com
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.chartmill.com
Is DEXCOM INC (NASDAQDXCM) on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill · November 11, 2024
Analyst Expectations For DexCom's Futurebenzinga.com
Via Benzinga · October 25, 2024
2 Excellent Healthcare Stocks to Hold Through the Next Decadefool.com
Via The Motley Fool · November 28, 2024
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Overfool.com
Via The Motley Fool · November 26, 2024
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Investfool.com
Via The Motley Fool · November 24, 2024
Large-Cap Stocks In Trouble - Sunday, Nov. 17talkmarkets.com
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.
Via Talk Markets · November 17, 2024
Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCombenzinga.com
Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest Form 13F on Thursday and disclosed its trading activity from the prior quarter.
Via Benzinga · November 14, 2024
1 Stock to Buy Near Its 52-Week Low and Hold for 10 Yearsfool.com
This medical device company is down but not out.
Via The Motley Fool · November 8, 2024
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continuesinvestors.com
Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024.
Via Investor's Business Daily · November 8, 2024
Why DexCom Stock Flopped on Fridayfool.com
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.
Via The Motley Fool · October 25, 2024